Hillsdale Investment Management’s Regenxbio RGNX Stock Holding History

Hillsdale Investment Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-130	Closed	-$9K	–	538
2018 Q2	$9K	Buy	+130	New	+$6.21K	﹤0.01%	373

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Hillsdale Investment Management's RGNX Position: Q3 2018 in Review

Hillsdale Investment Management sold out of Regenxbio (RGNX) in Q3 2018, closing a stake of 130 shares — an estimated $9K sold.

Hillsdale Investment Management first reported a position in RGNX in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 203 funds tracked by Wall St. Rank hold RGNX as of Q3 2018.

Hillsdale Investment Management reported no remaining Regenxbio position as of Q3 2018 after selling out during the quarter.
Hillsdale Investment Management sold 130 Regenxbio shares in Q3 2018, an estimated $9K.
Hillsdale Investment Management first reported a position in Regenxbio in Q2 2018 and held it in 1 quarter.
Hillsdale Investment Management's Regenxbio position peaked at $9K in Q2 2018.
203 funds tracked by Wall St. Rank held Regenxbio as of Q3 2018.

Based on Hillsdale Investment Management's 13F filing for Q3 2018, filed 9 Nov 2018.